AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01209715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
Study NCT01209715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone /salmeterol
Description: Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
Study NCT01209715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone /salmeterol
Description: Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
Study NCT02016287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy
Description: Sequential paclitaxel chemotherapy and radiotherapy
Study NCT01662999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Study NCT01569269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation.
Study NCT01569269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Intervention
Description: The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
Study NCT01569269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
Study NCT01537107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given PO
Study NCT01537107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study NCT01569269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Holistic Education
Description: The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
Study NCT02632344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
Study NCT01695538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
Study NCT00194454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified cognitive behavioral therapy plus problem-solving
Description: 9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
Study NCT00194454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
Study NCT02451267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy treatment with aerobic exercise
Description: neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
Study NCT02451267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy treatment
Description: neck exercise strengthening program with neck massage
Study NCT03517215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced CB-ASP
Description: The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
Study NCT03517215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CB-ASP
Description: A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
Study NCT02820636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S-CBT
Description: The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual \& 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication \& trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
Study NCT02820636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
Study NCT02880761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment guiding surgery and puncture for AVF
Description: Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
Study NCT03644693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Formulation Containing Exogenous Ketones
Description: A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.
Study NCT03644693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formulation
Description: A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
Study NCT00961207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
Study NCT00859430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 1000 mg Tablet
Study NCT00859430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra®
Description: 1000 mg Tablet
Study NCT01537107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study NCT01537107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies
Study NCT01537107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01537107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01537107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies
Study NCT02879396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA4LE Program
Description: 1. Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~2. Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~3. Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~4. Patient understanding of red flag indicators of worsening condition and appropriate next steps~5. Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness \& Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms
Study NCT03003299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Description: Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
Study NCT01001299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug cocktail
Description: Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
Study NCT01001299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg orally twice daily
Study NCT04304547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
Description: Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet
Study NCT04304547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,
Description: Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once
Study NCT04304547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-348 T2, CKD-348 T1, CKD-828, D097, D337
Description: Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet
Study NCT01836874 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
Study NCT02373501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-abdominal repair
Description: Intra abdominal repair of uterine incision
Study NCT02373501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal repair
Description: Extra abdominal repair of uterine incision
Study NCT01817517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa Deep Brain Stimulation System
Study NCT03479645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serial text messages and mailed FIT kit
Description: 1. Pre-alert SMS offering Opt-out of mailed FIT kit~2. Mailed home FIT kit~3. SMS A - Reciprocity message~4. SMS B - Offer for second FIT kit if lost/did not receive~   * Plus SMS A + C if second mailed FIT is requested.~5. SMS C - Salience message
Study NCT00928122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Presbyopia
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
Study NCT00928122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal correction of Myopia
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
Study NCT00928122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Hyperopia
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
Study NCT00928122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Myopia incl. Astigmatism
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
Study NCT00928122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Hyperopia incl. Astigmatism
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
Study NCT00575835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D twice daily
Description: Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
Study NCT00575835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 oil three times in a year
Description: Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
Study NCT04291001 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENG implant
Description: This is an FDA-approved contraceptive device
Study NCT04291001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ulipristal acetate
Description: This is an FDA-approved oral emergency contraceptive
Study NCT00251160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrothermal arthroscopic capsulorrhaphy (ETAC)
Description: The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
Study NCT00251160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open inferior capsular shift (ICS)
Description: MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
Study NCT04676971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Study NCT04676971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline solution)
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Study NCT00924170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-2
Description: Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
Study NCT00924170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days 1-3:~Patients 1-7, 10-14, and >18:25mg/m\^2/day Patients 8 - 9:30 mg/m\^2/day Patients 15- 17:20 mg/m\^2/day
Study NCT00924170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-3:~Patients 1-7, 10 -14, and >18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day
Study NCT01190423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Therapy for young adults
Description: Individual and Group Therapy Sessions
Study NCT05121571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT05121571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: sorafenib 400mg bid
Study NCT03642093 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
Study NCT03642093 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
Study NCT03642093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Walking and Inspiratory Muscle Training
Study NCT03642093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Description: Walking and Inspiratory Muscle Training
Study NCT02598570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvelisib
Description: Duvelisib will be administered orally as a fixed dose in 28-day cycles.
Study NCT02550977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
Study NCT03585127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
Study NCT03585127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar Therapy
Description: Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
Study NCT02486627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plazomicin
Study NCT02486627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem